Citrus Bergamot for Cholesterol: LDL, Triglycerides & Realistic Result

By Erin Rose · Updated July 19, 2026 · Methodology

Informational summary of published research — not medical advice. Talk to your doctor before changing any cholesterol treatment, and before combining bergamot with a statin. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Gliozzi 2013: the statin-adjunct trial

Gliozzi 2013 enrolled 77 patients with elevated LDL/triglycerides into five groups (placebo, rosuvastatin 10mg, rosuvastatin 20mg, BPF 1000mg alone, and BPF 1000mg plus rosuvastatin 10mg) for 30 days. The primary measures were LDL-C and oxidative-stress biomarkers (LOX-1 expression, phospho-PKB). The result: adding BPF 1000mg to a 10mg rosuvastatin dose significantly enhanced the statin's LDL-lowering effect and reduced oxidative-damage markers — a real, useful, and directly relevant finding for anyone thinking about bergamot as a statin adjunct. The caveats matter here: despite being described as "placebo-controlled," the trial was open-label, not double-blind, group sizes were small (15–16 per arm), and it comes from the Mollace/Catanzaro group — the institution that originated BPF and holds commercial interest in it.

Capomolla 2019: the dose-response trial

Capomolla 2019 randomized 52 obese patients with metabolic syndrome (45 completed, 15/arm) to placebo, BPE-C 650mg/day, or BPE-C 1,300mg/day for 90 days, tracking the atherogenic index of plasma (AIP) as the primary measure. The high-dose group's numbers are the largest in this evidence pack: fasting glucose down 18.1%, triglycerides down 32%, cholesterol parameters down as much as 41.4%, and AIP falling below 0.2. The trial also reported a 14.8% body-weight reduction and 15.9% BMI reduction in the high-dose arm — a genuinely large figure for a lipid-focused extract that deserves a second look before being taken at face value. All authors are affiliated with Magna Graecia University of Catanzaro / Nutramed S.C.A.R.L. — the same institutional ecosystem that developed and commercializes BPF. No financial conflict is declared, but that institutional tie is a real, disclosable pattern even without one.

Pierdomenico 2023: the independent-adjacent RCT

Pierdomenico 2023 combined a cell-culture mechanism study with a double-blind, placebo-controlled RCT in 50 healthy, moderately hypercholesterolemic adults given 400mg/day of a whole-fruit extract (Brumex™) for 12 weeks. The trial found significant reductions in total cholesterol, triglycerides, LDL-C, non-HDL-C, ApoB100, fasting glucose, and liver enzymes versus placebo — a genuinely well-designed, double-blind trial at the lowest effective dose in this evidence pack. The disclosure: a co-author (Riccioni) is from Esserre Pharma Srl, the manufacturer of the Brumex™ ingredient being tested — direct industry co-authorship, and the Cicero/Bologna research group involved discloses grants from nutraceutical manufacturers in related work.

The wider, more skeptical context

Weigh those three trials against Lamiquiz-Moneo 2020, a systematic review from an independent Spanish lipid unit with no bergamot-industry tie. Screening 442 studies down to 12 that met eligibility, it found 75% showed a significant decrease in total cholesterol, triglycerides, and LDL-C — real signal — across a wide range (TC −12.3% to −31.3%, LDL-C −7.6% to −40.8%, TG −11.5% to −39.5%), with 8 of 12 trials also finding an HDL-C increase. But the review's own conclusion is the load-bearing sentence: "studies had heterogeneous designs and scientific quality of studies was quite limited." A separate single-arm study without a placebo group, Toth 2015, reported one of the largest effects in the literature (LDL −19.6% over 6 months, plus a striking carotid intima-media thickness reduction) — but with no control arm, diet changes, regression to the mean, or observer effects can't be ruled out, and a result that dramatic needs independent replication before it's treated as settled.

The honest framing: a risk-marker mover, not a proven treatment

Every citation on this page measures a surrogate lipid or metabolic marker — LDL-C, triglycerides, HDL-C, fasting glucose, the atherogenic index — over 30 days to 12 weeks. None measured a hard cardiovascular outcome like heart attack, stroke, or death, the way statin outcome trials are designed to. That distinction matters: lowering LDL by even 10–20% is a real, worthwhile risk-factor change worth discussing with a doctor, especially alongside diet and exercise — but it is not the same claim as "bergamot prevents heart disease" or "bergamot replaces your statin," and no evidence in this pack supports either of those framings.

As an Amazon Associate we earn from qualifying purchases. Ranked by disclosed standardization, never commissions.

Frequently asked questions

Related

• Citrus Bergamot: what it is & who it's for
• Dosage Guide — the trial dose range, honestly
• Best Citrus Bergamot Supplement — ranked by standardization
• Does Citrus Bergamot Actually Lower Cholesterol? — the full evidence-quality reckoning
• CoQ10 for Statins — the site's other statin-adjunct page
• Psyllium for Cholesterol — the site's one FDA-authorized cholesterol claim, for contrast

Sources